Rx Countermeasures: HHS Launching "Pivotal Studies" To Engage Industry

HHS is hoping to redefine its relationship with biotech and pharmaceutical firms that are developing Rx countermeasures though a series of "pivotal studies" under which government works more closely with industry at the beginning stages of development